Abstract:Breast cancer is the second most common cancer and a leading cause of cancer death in women. Specifically, estrogen receptor-α (ERα)-negative breast cancers are clinically more aggressive and normally do not respond to conventional hormone-directed therapies such as tamoxifen. Although epigenetic-based therapies such as 5-aza-2'-deoxycytidine and/or trichostatin A as DNA methyltransferase (DNMT) and histone deacetylase (HDAC) inhibitors, respectively, can regulate the expression of ERα, this can often lead to a number of side effects. Plant-based dietary compounds such as resveratrol and pterostilbene in novel combinatorial therapy provides new avenues to target these side effects and provide similar results with a higher level of safety. Here, we report that combinatorial resveratrol and pterostilbene leads to the reactivation of ERα expression in ERα-negative breast cancer cells in a time-dependent manner. Chromatin immunoprecipitation analysis of the ERα promoter in each cell type revealed an increase in enrichment of acetyl-H3, acetyl-H3lysine9 (H3K9) and acetyl-H4 active chromatin markers in the ERα promoter region after combinatorial treatment. This treatment also resulted in a significant change in HDAC and histone acetyl transferase (HAT) enzyme activity in these cells after 3 days of treatments. The combination resulted in a significant decrease in DNMT enzyme activity and 5-methylcytosine levels in MDA-MB-157 breast cancer cells. Moreover, reactivation of ERα expression by resveratrol combined with pterostilbene was found to sensitize ERα-dependent response to 17β-estradiol (E2)-mediated cellular proliferation and antagonist 4-hydroxytamoxifen (4-OHT)-mediated inhibition of cellular proliferation in ERα-negative breast cancer cells. E2 and 4-OHT further affected the ERα-responsive downstream progesterone receptor (PGR) gene in ERα reactivated MDA-MB-157 cells. Collectively, our findings provide a new and safer way of restoring ERα expression by regulating epigenetic mechanisms with the use of phytochemicals in combinatorial therapy. This combination can further provide effective treatment options for hormonal refractory breast cancer with available anti-hormonal therapy.

Pyrimidine–triazole‐tethered tert‐butyl‐piperazine‐carboxylate suppresses breast cancer by targeting estrogen receptor signaling and β‐catenin activation

A Novel Biphenyl Urea Derivate Inhibits the Invasion of Breast Cancer Through the Modulation of CXCR4

Novel Chemicals Derived from Tadalafil Exhibit PRMT5 Inhibition and Promising Activities against Breast Cancer

Design and synthesis of novel benzothiophene analogs as selective estrogen receptor covalent antagonists against breast cancer

Pi3k/Mtor Dual Inhibitor Bez235 and Histone Deacetylase Inhibitor Trichostatin A Synergistically Exert Anti-Tumor Activity in Breast Cancer

Chlorotoxin Targets ERα/VASP Signaling Pathway to Combat Breast Cancer

Rapid Induction of the Unfolded Protein Response and Apoptosis by Estrogen Mimic TTC-352 for the Treatment of Endocrine-Resistant Breast Cancer

Pharmacophore Modeling, 3D QSAR, Molecular Dynamics Studies and Virtual Screening on Pyrazolopyrimidines as anti-Breast Cancer Agents

Anti-breast Cancer Activity of Selected 1,3,5-Triazines Via Modulation of EGFR-TK

Thiouracil and triazole conjugate induces autophagy through the downregulation of Wnt/β‐catenin signaling pathway in human breast cancer cells

A Novel Combinatorial Epigenetic Therapy Using Resveratrol and Pterostilbene for Restoring Estrogen Receptor-α (ERα) Expression in ERα-Negative Breast Cancer Cells

Tweaking EMT and MDR dynamics to constrain triple-negative breast cancer invasiveness by EGFR and Wnt/β-catenin signaling regulation

Glucosyltriazole amphiphile treatment attenuates breast cancer by modulating the AMPK signaling

Targeting EMT using low-dose Teniposide by downregulating ZEB2-driven activation of RNA polymerase I in breast cancer

Targeting Pyruvate Carboxylase by a Small Molecule Suppresses Breast Cancer Progression

Synthesis, In vitro and In silico Studies of Novel bis‐triazolopyridopyrimidines from Curcumin Analogues as Potential Aromatase Agents

Peptide Inhibitor Targeting the Extraterminal Domain in BRD4 Potently Suppresses Breast Cancer Both In Vitro and In Vivo

The Anti-Cancer Effects of Mitochondrial-Targeted Triphenylphosphonium–Resveratrol Conjugate on Breast Cancer Cells

A novel taspine derivative, HMQ1611, inhibits breast cancer cell growth via estrogen receptor α and EGF receptor signaling pathways.

Discovery of a Tetrahydroisoquinoline-Based CDK9-cyclin T1 Protein–protein Interaction Inhibitor As an Anti-Proliferative and Anti-Migration Agent Against Triple-Negative Breast Cancer Cells

Cholesteryl ester transfer protein knock‐down in conjunction with a cholesterol‐depleting agent decreases tamoxifen resistance in breast cancer cells